India's weight-loss drug market shows maturity

India's market for anti-obesity drugs is exhibiting a notable maturity, moving beyond initial rapid adoption to a more considered phase. While affordable generic options are now available, their uptake is proceeding with caution. This nuanced approach is shaped by market forces, sensible regulation, and increasing consumer awareness, rather than a restrictive ban.

The initial wave of users for these drugs largely comprised affluent individuals for whom weight loss was the primary objective, irrespective of cost. The subsequent group of eligible consumers is more price-sensitive, and despite the availability of cheaper generic alternatives, the overall cost remains a significant factor.

Semaglutide, a key drug in this market, has not been banned. Instead, 13 pharmaceutical companies have introduced 26 generic brands. The government's strategy involves raising public awareness and implementing regulatory guardrails. Drug regulators have issued advisories that prohibit direct-to-consumer advertising and promotion of prescription weight-loss medications. Concurrently, authorities are monitoring for unauthorized sales channels, such as those involving gym trainers, dieticians, and online pharmacies, to prevent misuse.

A crucial element in shifting consumer perception away from viewing these drugs as a simple quick fix has been the effort to address information asymmetry. Medical professionals and reputable institutions are actively informing the public about the serious potential side effects associated with misuse. These risks include muscle loss, malnutrition, pancreatitis, and the likelihood of rapid weight regain once medication is stopped. This enhanced understanding and wider dissemination of safety information are fostering more informed consumer choices.